Ecallantide: Difference between revisions
Kurtucla05 (talk | contribs) (Created page with "==General== *Type: Kallikrein inhibitor for angioedema *Dosage Forms: 30mg *Routes of Administration: SQ *Common Trade Names: Kalbitor ==Adult Dosing== *30mg SQ *Max 60mg/ 2...") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Acute hereditary angioedema]]=== | |||
*30mg SQ | *30mg SQ | ||
*Max 60mg/ 24 hr | *Max 60mg/ 24 hr | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Acute hereditary angioedema]] (>12yo)=== | |||
*30mg SQ | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | ||
| Line 29: | Line 32: | ||
*diarrhea | *diarrhea | ||
*URI | *URI | ||
*injection site | *injection site reaction | ||
*nasopharyngitis | *nasopharyngitis | ||
*vomiting | *vomiting | ||
| Line 44: | Line 47: | ||
==Comments== | ==Comments== | ||
*Plasma kallikrein works as cofactor to formation of bradykinin which is implicated in angioedema | *Plasma kallikrein works as cofactor to formation of bradykinin which is implicated in angioedema | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Ecallantide]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
*[[Angioedema (Upper Airway)]] | *[[Angioedema (Upper Airway)]] | ||
| Line 50: | Line 70: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
Latest revision as of 21:56, 20 March 2026
General
- Type: Kallikrein inhibitor for angioedema
- Dosage Forms: 30mg
- Routes of Administration: SQ
- Common Trade Names: Kalbitor
Adult Dosing
Acute hereditary angioedema
- 30mg SQ
- Max 60mg/ 24 hr
Pediatric Dosing
Acute hereditary angioedema (>12yo)
- 30mg SQ
Special Populations
- Pregnancy Rating:C
- Lactation risk:Safety Unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- hypersensitivity reaction
Common
- headache
- nausea
- fatigue
- diarrhea
- URI
- injection site reaction
- nasopharyngitis
- vomiting
- pruritus
- abdominal pain
- fever
- anaphylaxis
Pharmacology
- Half-life: 2h
- Metabolism: CYP450
- Excretion: Urine
- Mechanism of Action: selectively, reversibly inhibits plasma kallikrein, preventing bradykinin generation
Comments
- Plasma kallikrein works as cofactor to formation of bradykinin which is implicated in angioedema
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Angioedema | 10 mg SC x3 at different sites (30 mg total) | Kallikrein inhibitor (HAE) | SC | Adult |